TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration
Rhea-AI Filing Summary
TScan Therapeutics, Inc. (TCRX) reports that Amgen has elected to terminate in its entirety their Research Collaboration and License Agreement, which focused on using TScan’s target discovery platform to identify T‑cell antigens in Crohn’s disease. Amgen is exercising a contractual right to terminate with 90 days’ prior written notice, making the termination effective November 10, 2026, and TScan will incur no early termination penalty. TScan had previously received a $30.0 million non‑refundable upfront payment in 2023; the agreement also contemplated more than $500 million in success‑based milestones and tiered single‑digit royalties on future product sales. After termination, TScan does not expect future milestone or royalty payments from this collaboration unless Amgen or its affiliates or sublicensees continue to exploit product candidates, in which case applicable milestones and royalties would survive under the agreement’s terms.
Positive
- None.
Negative
- Termination of Amgen collaboration removes potential $500+ million in future milestones and associated royalty revenue.
- Loss of an exclusive, worldwide development and commercialization partner for Crohn’s disease product candidates created under the collaboration.
- TScan must wind down current research activities under the plan, reducing collaboration-driven development in Crohn’s disease.
8-K Event Classification
Item 1.02 — Termination of a Material Definitive Agreement
1 item
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Key Figures
Upfront payment: $30.0 million
Potential milestones: Over $500 million
Notice period: 90 days
+1 more
4 metrics
Upfront payment
$30.0 million
Non-refundable upfront payment received by TScan in 2023 under the Amgen collaboration
Potential milestones
Over $500 million
Aggregate success-based milestone payments contemplated by the collaboration agreement
Notice period
90 days
Required prior written notice for Amgen to terminate the collaboration agreement
Termination effective date
November 10, 2026
Date on which the collaboration agreement termination becomes effective
Key Terms
Research Collaboration and License Agreement, success-based milestone payments, tiered single-digit royalty payments, commercially reasonable efforts
4 terms
Research Collaboration and License Agreement regulatory
"Amgen of its election to terminate, in its entirety, the Research Collaboration and License Agreement"
success-based milestone payments financial
"success-based milestone payments of over $500 million in the aggregate"
tiered single-digit royalty payments financial
"and tiered single-digit royalty payments on net sales of products"
commercially reasonable efforts regulatory
"the Company is obligated to use commercially reasonable efforts to promptly and efficiently wind down"
FAQ
What did Amgen terminate in its collaboration with TScan Therapeutics (TCRX)?
Amgen elected to terminate in its entirety the Research Collaboration and License Agreement with TScan, covering use of TScan’s target discovery platform to identify T‑cell antigens in Crohn’s disease and Amgen’s exclusive worldwide rights to develop resulting product candidates.
When does the terminated Amgen–TScan (TCRX) collaboration officially end?
The termination becomes effective on November 10, 2026. Amgen exercised its right to terminate the agreement upon providing 90 days’ prior written notice, and TScan must wind down its activities under the then‑current research plan.
How much upfront cash did TScan Therapeutics (TCRX) receive from the Amgen deal?
TScan received a $30.0 million non‑refundable upfront payment in 2023 under the Amgen collaboration. This amount has already been paid; termination mainly affects potential future milestones and royalty streams rather than this upfront cash.
What potential milestone payments are affected by the Amgen–TScan (TCRX) termination?
The original agreement included success‑based milestone payments of over $500 million in aggregate. Following termination, TScan does not expect to receive these milestones unless Amgen or its affiliates or sublicensees continue to exploit product candidates from the collaboration.
Will TScan Therapeutics (TCRX) owe any penalties due to Amgen’s termination?
No early termination penalty is payable by TScan. Under the agreement’s terms, Amgen can terminate with 90 days’ written notice, and TScan’s main obligations are to promptly and efficiently wind down research activities under the current plan.
Can TScan Therapeutics (TCRX) still earn royalties from the former Amgen collaboration?
Royalties are only possible if Amgen, its affiliates or sublicensees continue to exploit product candidates created in the collaboration. In that case, applicable milestone and tiered single‑digit royalty obligations would survive according to the agreement’s terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
